



ABN 53 075 582 740

ASX ANNOUNCEMENT

31 August 2016

Bionomics Appoints Alan Fisher Non-Executive Director

Trevor Tappenden to retire from Board

Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, has appointed Mr Alan Fisher to the Board as Non-Executive Director.

Mr Fisher spent 24 years at world-leading accounting firm Coopers & Lybrand including as Lead Advisory Partner Corporate Finance where he headed and grew the Melbourne Corporate Finance Division. Following this tenure Mr Fisher developed his own business as a corporate adviser and for the past 19 years has specialized in M&A, business turnarounds and capital raising for small cap companies.

Mr Fisher's appointment will strengthen the Board in finance and strategy. He also has deep experience in audit and risk management.

Mr Fisher, a Chartered Accountant, is currently a Non-Executive Chairman for Centrepoint Alliance Limited, Non-Executive Director and Chair of the Audit and Risk Committee of IDT Australia Limited, and Non-Executive Chairman of Australian Renewable Fuels Limited. He is also currently the Managing Director of Melbourne-based DMC Corporate.

Current Non-Executive Director Mr Trevor Tappenden has decided, having served on the Board for 10 years, not to stand for re-election and will retire at the Company's Annual General Meeting (AGM) in November.

These changes follow the June appointments of Mr David Wilson, the Executive Chairman and CEO of a specialist London-based global life sciences corporate advisory firm and Mr Peter Turner with his experience as a senior international executive with a long history in the life sciences industry in Board and management roles with CSL Limited.

Incoming Chairman Dr Errol De Souza said, "Mr Fisher has strong business acumen and his financial technical base makes him ideally suited to joining the Bionomics Board. A pragmatic financial expert, his experience will benefit the company and I am delighted to welcome someone of his calibre and experience."

"I also record my thanks on behalf of all in the Company and the Board for Trevor Tappenden's contributions as a Director and Chairman of the Audit and Risk Management Committee."

FOR FURTHER INFORMATION PLEASE CONTACT:

Australia

Monsoon Communications
Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

US

Stern IR, Inc.
Beth Del Giacco
+1 212 362 1200
beth@sternir.com

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder and for post-traumatic stress disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. The Company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 entered clinical trials in the first quarter of 2016. Bionomics has strategic partnerships with Merck & Co., Inc (known as MSD outside the United States and Canada) in pain and cognition.

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this announcement.